Axitinib-13C, d3

Axitinib-13C, d3 is a 13C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50 values of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1][2].

Product Specifications

CAS Number

[1261432-00-1]

Product Name Alternative

AG-013736 13CD3

UNSPSC

12352005

Hazard Statement

H302+H312+H332-H315-H319

Target

PDGFR; VEGFR

Type

Isotope-Labeled Compounds

Related Pathways

Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Purity

97.80

Solubility

10 mM in DMSO|DMF : ≥ 0.25mg/mL|DMSO : ≥ 2.5mg/mL

Smiles

[2H][13C]([2H])([2H])NC(C(C=CC=C1)=C1SC2=CC=C3C(/C=C/C4=CC=CC=N4)=NNC3=C2)=O

Molecular Formula

C21 13CH15D3N4OS

Molecular Weight

390.48

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Fenton BM, et al. The addition of AG-013736 to rractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 2007 Oct 15;67 (20) :9921-8.; Hu-Lowe DD, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14 (22) :7272-83; Allen E, et al. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell Rep. 2016 May 10;15 (6) :1144-60.